ARTICLE / CLIENT ALERT
FDA Issues Enforcement Policy for Digital Health Therapeutic Devices for Psychiatric Disorders During COVID-19
April 21, 2020
Read time: 7 min
The Food and Drug Administration issued an enforcement policy on the use of digital health devices that are considered therapeutic for psychiatric disorders during the Coronavirus (COVID-19) public health emergency. The agency clarified it does intend to address low-risk digital health products and also clarified that standard video platforms used for telemedicine are not medical devices. This update signifies FDA’s attempt to waive certain review requirements during this health emergency.
On April 14, 2020, the US Food and Drug Administration (FDA) issued its Enforcement Policy for Digital Health Devices For Treating Psychiatric Disorders During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency. In the policy, FDA announced its intent to exercise enforcement discretion with respect to certain regulatory requirements—i.e., the 510(k), registration and listing, and unique device identifier requirements, among others—for digital health therapeutic devices for psychiatric disorders during the public health emergency. FDA also clarified that it does not intend to assess low-risk digital health products that make certain claims for mental health or psychiatric conditions to determine whether they are devices, or to enforce applicable regulatory requirements if they are devices. Practically, this means that FDA does not intend to apply or enforce medical device requirements for these products during the public health emergency. FDA also clarified that standard videoconferencing software used for telemedicine is not a medical device.
The enforcement policy reflects the agency’s attempt to address concerns that patients may have limited access to face-to-face treatment, monitoring and interventions while social distance orders remain in effect.
Computerized Behavioral Therapy Devices and Other Digital Health Therapeutic Devices for Psychiatric Disorders
Computerized behavioral therapy devices for psychiatric disorders are class II, prescription-only devices regulated under 21 CFR § 882.5801 (product code PWE) that provide computerized, condition-specific behavioral therapy as an adjunct to clinician-supervised outpatient treatments. These products use various tools, such as daily treatment sessions, coaching, reminders, and assessment or monitoring of symptoms, to help patients manage symptoms and care. FDA has cleared these products for use for disorders such as substance use disorder and chronic insomnia. Other digital health therapeutic devices that operate using a different fundamental technology that do not fit within 21 CFR § 882.5801 are also subject to the enforcement policy, as are computerized therapy devices that are outside the scope of 21 CFR § 882.5801 (e.g., non-prescription devices). While FDA did not specifically describe the other types of digital health therapeutic devices that would be subject to the enforcement policy, the guiding principles suggest that tools that use wearables, artificial intelligence or machine learning, or principles such as Acceptance Commitment Therapy or other types of therapies, would be subject to the policy. The policy also does not explicitly address post-market modifications to previously cleared digital health devices for psychiatric disorders.
The enforcement policy does not apply to devices for the treatment of underlying psychiatric conditions that may require an urgent or immediate clinical intervention and for which delay of such intervention may pose significant harm to the patient (e.g., treatment of suicidality). FDA did not provide concrete examples of the underlying conditions that would not be eligible for enforcement discretion under the policy. However, the list of psychiatric conditions that FDA identified as generally within scope for the enforcement policy provides a clue as to which conditions may be out of scope. The enforcement policy will be available to devices for the treatment of psychiatric conditions such as obsessive compulsive disorder, generalized anxiety disorder, insomnia, major depressive disorder, substance abuse disorder, post-traumatic stress disorder, autism spectrum disorder and attention deficit hyperactivity disorder. While FDA stated that the examples of in-scope conditions are not exhaustive, manufacturers and developers should evaluate the clinical severity of the symptoms and risks associated with the underlying disorder to determine whether their device is in scope for enforcement discretion. Companies should consider providing contemporaneous documentation and justifications (e.g., clinical, regulatory, medical and legal) for decisions regarding the applicability of this policy.
In order to mitigate risk, FDA describes various performance, software validation, cybersecurity, labeling (including precautions, contraindications and instructions for use) and other risk management processes that developers should implement before proceeding under the policy.
Devices must satisfy the risk management criteria described in the policy to be exempt from applicable medical device requirements. These requirements include:
- The premarket notification requirement under section 510(k) of the Federal Food, Drug, and Cosmetic Act and 21 CFR § 807.81
- Reports of corrections and removals under 21 CFR Part 806
- Registration and listing under 21 CFR Part 807
- Unique Device Identification under 21 CFR Part 830 and 21 CFR § 801.20 where such devices do not create undue risk.
FDA also does not intend to enforce compliance with the special controls identified in 21 CFR § 882.5801 (i.e., prospective clinical data). These exemptions do not apply to already-cleared computerized behavioral therapy devices.
Low Risk General Wellness Devices
Consistent with the 21st Century Cures Act, FDA reiterates that software functions intended to maintain or encourage a healthy lifestyle that are unrelated to a specific disease or condition are not devices and thus are not subject to device requirements. For example, items used for the following purposes would not be considered devices:
- Promoting relaxation, mindfulness or meditation
- Reducing stress, fatigue or feelings of isolation
- Promoting good sleep, improving the sleep experience, having more relaxing or restful sleep, or sleeping through the night or all night
- Reducing stress and promoting a positive mental outlook, including helping users live well during the COVID-19 public health emergency
- Reminding users to keep safe physical (or social) distancing practices during the current public health emergency.
FDA also gives several examples of software functions related to psychiatric conditions that may meet the definition of a device but for which FDA does not intend to enforce device requirements at this time because they pose a low risk. These include functions that:
- Promote, track or encourage choices that, as part of a healthy lifestyle, may help users live well with, or reduce the risk of, certain chronic psychiatric diseases or conditions, where the link between living well and reducing the risk or impact of the disease or condition is well understood (e.g., depression, anxiety, obsessive compulsive disorder, autism, attention deficient hyperactive disorder)
- Help patients with diagnosed psychiatric conditions maintain their behavioral coping skills (e.g., “Skill of the Day” behavioral techniques or audio messages)
- Encourage users to notice, accept and embrace difficult or previously unwanted thoughts or feelings in order to open up to and avoid overreactions to these thoughts or feelings
- Display, at opportune times, images or messages to help stop addictive behavior
- Help users self-manage their disease or conditions without providing specific treatment or treatment suggestions
- Use a checklist or a questionnaire of common signs and symptoms for a psychiatric disorder and provide a list of possible medical conditions and advice on when to consult a healthcare provider
- Guide users through a questionnaire of signs or symptoms for a psychiatric disorder and provide a recommendation for the type of healthcare facility most appropriate to the user’s needs.
Implications
The enforcement policy is most notable as an expression of FDA’s willingness to temporarily waive premarket review requirements for computerized behavioral therapy products during this public health emergency. The enforcement policy also reiterates principles articulated in the Cures Act and clarifies the agency’s general wellness product guidance, respectively, serving as a helpful summary of the agency’s oversight of digital health products for certain psychiatric disorders.
Corporate Management in Crisis Mode: An Overview of the Main Legal Management Parameters of a Credit Institution
ARTICLE
Corporate Management in Crisis Mode: An Overview of the Main Legal Management Parameters of a Credit Institution
April 21, 2020
Read time: 2 min
The crisis currently caused by the SARS-CoV-2 virus or coronavirus (COVID-19)-pandemic is hitting the German and global economy unexpectedly and with unprecedented severity. In contrast to the financial crisis of 2008/2009, the banking industry is neither the trigger nor the culprit, nor is it at the centre of the rescue measures launched by the German Federal States, the German Federal Government and the EU. Rather, the credit institutions are “first responders” in this crisis, providing the battered economy with liquidity under the backing of the KfW (a German state-owned development bank) at short notice.
But what about the credit institutions themselves? In the aftermath of the financial crisis, numerous new regulations were introduced, which made it clear that credit institutions must exercise the utmost caution. Now, crisis management requires them to act quickly and efficiently. But the credit institutions themselves must also safeguard their balance sheet and ensure ongoing business activities during the crisis. Further, they need to take care not to get into difficulties due to falling share prices and a nationwide fluctuating economy.
This article provides an overview of the duties to which the managers of a credit institution are subject in view of the current new challenges, taking into account the reactions already received from the regulatory supervisory authorities, the European Central Bank (ECB) and the German Federal Financial Supervisory Authority (BaFin).
‘Proposed Federal Pandemic Risk Reinsurance Program: What We Know So Far’
ARTICLE
‘Proposed Federal Pandemic Risk Reinsurance Program: What We Know So Far’
April 21, 2020
Read time: 1 min
Texas Governor Reduces Restrictions on Surgical and Medical Procedures
ARTICLE / CLIENT ALERT
Texas Governor Reduces Restrictions on Surgical and Medical Procedures
April 22, 2020
Read time: 5 min
This alert was originally published on April 20, 2020, and was updated on April 22, 2020, to reflect new developments.
On April 17, 2020, Texas Governor Abbott issued an executive order permitting healthcare facilities to provide less urgent surgical and medical procedures. This order is in effect until May 8, 2020. On April 21, 2020, the Texas Medical Board issued a new emergency rule and new FAQs in response to this order.
In a move to re-open the state economy, Texas Governor Abbott issued an executive order, EO-GA-15, on April 17, 2020, that pulls back on a prior executive order restricting most surgical and medical procedures. The governor’s prior order, EO-GA-09, expired on April 21, 2020, and limited licensed facilities from providing any surgery or procedure not “immediately medically necessary to correct a serious medical condition of, or to preserve the life of, a patient who without immediate performance of the surgery or procedure would be at risk for serious adverse medical consequences or death, as determined by the patient’s physician.”
The new order, which is in effect until May 8, 2020, continues to impose restrictions on procedures but allows for procedures of a less urgent nature. Notably, this order removes reference to immediate medical need. Instead, the new order requires that the surgery or procedure be “medically necessary to diagnose or correct a serious medical condition of, or to preserve the life of a patient, who, without timely performance. . . would be at risk for serious adverse medical consequences or death, as determined by the patient’s physician.”
The new order provides that this restriction does not apply to any surgery or procedure performed in a licensed healthcare facility that has certified in writing to the Texas Health and Human Services Commission (THHS) that (1) it will reserve at least 25% of its hospital capacity for treatment of Coronavirus (COVID-19) patients, accounting for the range of clinical severity of COVID-19 patients; and (2) it will not request any personal protective equipment (PPE) from any public source, whether federal, state or local, for the duration of the COVID-19 disaster. THHS published a guidance letter that includes required certification language and contact information for submitting any such certification.
Finally, the new order includes an exception for any procedure that would not deplete hospital capacity or PPE.
What This Means for Ambulatory Surgery Centers (ASCs)
While the new order does not specifically reference ASCs, the certification to be made to THHS in order to be exempt from the restriction arguably only contemplates hospitals. ASCs should consult experienced healthcare regulatory counsel regarding whether they can make this certification. Otherwise, unless unless the procedure would not deplete PPE, ASCs must comply with the restrictions imposed, such that they may only perform procedures that are medically necessary to diagnose or correct a serious medical condition that must be treated in a timely manner to avoid serious adverse medical consequences or death. While the patient’s physician has discretion to determine whether this standard is met, it is important for the physician to document the medical necessity for each procedure and any adverse consequences of delay, as the difference between a need for an “immediate” procedure as opposed to a “timely” procedure is not clearly defined.
On March 24, 20202, the Texas Medical Board (TMB) adopted an emergency rule in response to EO-GA-09 that made performance of a non-urgent elective procedure in violation of this executive order cause for temporary suspension, and required mandatory reporting of any violation. However, that emergency rule has now expired and on April 21, 2020, TMB issued a new emergency rule, along with new FAQs in response to EO-GA-15. The new emergency rule makes failure to follow the new order cause for suspension of a medical license, though there is no mandatory reporting duty. In the FAQs, TMB underscores the importance of physicians documenting any determination that a surgery or procedure was “urgent and necessary” in a patient’s medical record to evidence compliance with the new order. While the FAQs shed light on TMB’s interpretation of the new order, there are some inconsistencies between the new order and the FAQs. Due to the inconsistencies, providers should consult healthcare regulatory counsel.
What This Means for Hospitals
Hospitals must also comply with the order prohibiting elective procedures unless they can certify to the THHS regarding reserving 25% of capacity for COVID-19 patients and refraining from requesting PPE from any public source for the remainder of the COVID-19 disaster. Given the uncertainty of the length of the COVID-19 disaster, hospitals may have concerns about making such a certification and should consult with healthcare regulatory counsel on the implications of making such a certification.
Local Orders
While the governor stated in press conferences that it is his intent that local orders not supersede his executive order, EO-GA-15 does not specifically state that local orders shall not supersede it. This presents some ambiguity, and providers should consult healthcare regulatory counsel to review the local orders in light of EO-GA-15.
What Every Director Needs to Know
ARTICLE
What Every Director Needs to Know
April 20, 2020
Read time: 1 min

What Do Companies Have To Consider When Restarting Operations After Corona Loosening?
ARTICLE
What Do Companies Have To Consider When Restarting Operations After Corona Loosening?
April 20, 2020
Read time: 2 min
On Wednesday, April 15, 2020, the federal and state governments agreed on an exit strategy from the corona measures, according to which the restrictions on public life are to be gradually reduced step by step. However, the effects of the COVID-19 pandemic and the measures taken against it will continue to have a strong impact on the economy.
In an interview with Alexander Göbring of Unternehmeredition, Dr. Tobias Koppmann, partner at McDermott Will & Emery, Munich, specialized in Corporate/M&A/Private Equity and Dr. Jan Clasen, Partner at MT Management Team GmbH, Munich, specialized in Restructurings and Distressed M&A, provide considerations for companies to systematically prepare for further easing of restrictions and for the ramp-up of operations during this phase of the pandemic.
Corporate Governance in Crisis Mode: An Overview of the Main Legal Parameters of the Management of a Credit Institution
ARTICLE
Corporate Governance in Crisis Mode: An Overview of the Main Legal Parameters of the Management of a Credit Institution
April 20, 2020
Read time: 2 min
The crisis currently caused by the SARS-CoV-2 virus or coronavirus (COVID-19)-pandemic is hitting the German and global economy unexpectedly and with unprecedented severity. In contrast to the financial crisis of 2008/2009, the banking industry is neither the trigger nor the culprit, nor is it at the centre of the rescue measures launched by the German Federal States, the German Federal Government and the EU. Rather, the credit institutions are “first responders” in this crisis, providing the battered economy with liquidity under the backing of the KfW (a German state-owned development bank) at short notice.
But what about the credit institutions themselves? In the aftermath of the financial crisis, numerous new regulations were introduced, which made it clear that credit institutions must exercise the utmost caution. Now, crisis management requires them to act quickly and efficiently. But the credit institutions themselves must also safeguard their balance sheet and ensure ongoing business activities during the crisis. Further, they need to take care not to get into difficulties due to falling share prices and a nationwide fluctuating economy.
This article provides an overview of the duties to which the managers of a credit institution are subject in view of the current new challenges, taking into account the reactions already received from the regulatory supervisory authorities, the European Central Bank (ECB) and the German Federal Financial Supervisory Authority (BaFin).

The Impact Of The Coronavirus Crisis On Mergers And Acquisitions
ARTICLE
The Impact Of The Coronavirus Crisis On Mergers And Acquisitions
April 17, 2020
Read time: 1 min
CARES Act Refund Claim Guidance
ARTICLE
CARES Act Refund Claim Guidance
April 17, 2020
Read time: 1 min
The SEC is Watching Advisors’ COVID-19 Response
ARTICLE
The SEC is Watching Advisors’ COVID-19 Response
April 17, 2020
Read time: 1 min